Generics agree HIV price cut for off-patent drugs
21 April 2009
Emma Barraclough, London
UNITAID and the Clinton HIV/AIDS Initiative have agreed a deal with generic drugs makers that should cut the cost of paediatric and second-line antiretroviral (ARV) medicines used in the treatment of HIV/AIDS.
The deal, announced on Friday, should cut the price of one year's supply of the cheapest second-line ARVs by more than $100 to $590.
These medicines are supplied to 42 countries through two projects funded by UNITAID and implemented by Clinton's CHAI initiative.
Beyond the scope of the UNITAID projects, the reduced prices will be available to more than...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial